A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single
injection of Temferon, an investigational advanced therapy consisting of autologous
CD34+-enriched hematopoietic stem and progenitor cells exposed to transduction with a
lentiviral vector driving myeloid-specific interferon-ɑ2 expression, which will be
administered to up to 9 patients affected by multiple myeloma in early relapse after
intensive front line treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genenta Science
Collaborators:
Fondazione IRCCS Ospedale San Raffaele, Milan, Italy IRCCS San Raffaele